In 2nd deal of week, Ipsen buys Memo’s kidney transplant antibody
· nuala moran
AI Briefing
- • Ipsen SA acquires Memo Therapeutics AG for €700 million (US$797 million).
- • Memo's phase III-ready drug potravitug targets kidney transplant patients with BK virus-associated infections.
- • Ipsen's second deal this week follows a previous acquisition announced earlier in the week.
Context
Ipsen SA has made its second acquisition of the week, purchasing Memo Therapeutics AG for €700 million. The deal includes Memo's phase III-ready drug potravitug, which is used to treat BK virus-associated infections and nephropathy in kidney transplant patients.
The acquisition matters as it adds a new treatment to Ipsen's portfolio, specifically for immune-compromised kidney transplant patients.
Advertisement